false000167158400016715842024-06-072024-06-07

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 07, 2024

 

 

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37746

81-1567056

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2401 4th Avenue

Suite 1050

 

Seattle, Washington

 

98121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

APVO

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 7, 2024, Aptevo Therapeutics Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. Stockholders considered four proposals outlined below, each of which is described in more detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 23, 2024 (the “Proxy Statement”). The final voting results with respect to each of the proposals acted upon at the 2024 Annual Meeting are set forth below.

 

Proposal 1: Election of Directors

 

The following two nominees, each of whom were named in the Proxy Statement, were elected to serve on the Board of Directors to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, based on the following votes:

 

FOR

WITHHELD

BROKER
NON-VOTES

Daniel J. Abdun-Nabi

470,470

333,623

704,366

Grady Grant, III

470,517

333,576

704,366

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm for 2024

The appointment of Moss Adams LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2024 was approved based on the following votes:

 

FOR

AGAINST

ABSTAIN

1,271,108

232,874

4,477

Proposal 3: Approval of the Company's Second Amended and Restated 2018 Stock Incentive Plan

 

The Aptevo Therapeutics Inc. Second Amended and Restated 2018 Stock Incentive Plan was approved based on the following votes:

 

FOR

AGAINST

ABSTAIN

BROKER NON-VOTES

442,849

355,401

5,843

704,366

 

Proposal 4: Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officer compensation as disclosed in the Proxy Statement.

The non-binding advisory proposal was approved based on the following votes:

 

FOR

AGAINST

ABSTAIN

BROKER NON-VOTES

436,765

365,824

1,504

704,366

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

APTEVO THERAPEUTICS INC.

 

 

 

 

Date:

June 10, 2024

By:

/s/ Marvin L. White

 

 

 

Marvin L. White
President and Chief Executive Officer

 

v3.24.1.1.u2
Document And Entity Information
Jun. 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 07, 2024
Entity Registrant Name APTEVO THERAPEUTICS INC.
Entity Central Index Key 0001671584
Entity Emerging Growth Company false
Entity File Number 001-37746
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-1567056
Entity Address, Address Line One 2401 4th Avenue
Entity Address, Address Line Two Suite 1050
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98121
City Area Code (206)
Local Phone Number 838-0500
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol APVO
Security Exchange Name NASDAQ
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Aptevo Therapeutics Charts.
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Aptevo Therapeutics Charts.